ABSTRACT
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the 6 th most common cancer worldwide. In 2005, 400,000 cases of HNSCC were diagnosed worldwide. Laryngeal carcinoma is the second most common type of head and neck cancer after skin cancer and accounts for 3% of total cancer risk (1) . Alcohol/tobacco consumption is the most important risk factor for that neoplasia; nevertheless, since 1983 it has been suggested that human papilloma viruses have a role in HNSCC, mainly in the oropharynx. In the last years, some authors showed the implication of the HPV in the development of pre-carcinogenic lesions and of squamous cell carcinoma (2) . The infection by HPV has been associated to hyperplastic epithelial lesions, papilloma and warty carcinoma in skin and in different types of mucosa, including the anusgenital, cervical, urethral, tracheobronchial, nasal, laryngeal and oral mucosa tracts. The viral high-risk geno-types (oncogenic) such as 16, 18, 31, 33 and 35 are frequently associated to leukoplakia and squamous carcinoma (3) . Human papilloma virus is a small double-stranded DNA virus that is capable of infecting cutaneous and mucosal epithelium, resulting in a variety of pathological lesions (4) . Among the more than 100 different types of HPV identified, HPV16 is the most common high-risk virus. Its contribution to neoplastic progression is predominantly through the action of the viral oncoproteins E6 and E7. Expression of HPV16 E6 and E7 proteins is sufficient for the immortalization of primary human epithelial cells and induces histological abnormalities reminiscent of premalignant HPV-associated squameous intraepithelial lesions . According to the modern theory of carcinogenesis, a complex and multistep process is likely in the development of LSCC. Cancer is caused by uncontrolled proliferation of cells, which is itself induced by abnormalities of cell cycle regulatory mechanisms or activation of growth factors involved in cell proliferation and differentiation (6) . The p53 tumorsuppressor gene regulates cell cycle progression through induction of apoptosis at the G1/S checkpoint. It has been well documented that E6 and E7 oncoproteins alter normal cell growth control mechanisms by inactivating two well-characterized tumor suppressor proteins, p53 and retinoblastoma protein, respectively (7) . There is evidence that inherited differences in cell cycle control systems, DNA repair systems, and carcinogen-metabolizing enzymes or altered dominant and recessive oncogenes, genetic instability, and growth factor-linked signal transmission pathways could increase the risk for laryngeal cancer (8) . The transforming activity of high-risk HPV seems to depend primarily on deregulated expression of E6 and E7 HPV oncoproteins. The E5 HPV oncoprotein, also, seems to play a role in early growth stimulation of HPVinfected cells by an interaction with some cellular proteins, and in particular with growth factors receptors, and to alter the cell response to signals for growth and differentiation (9) . Epidermal growth factor receptor is composed of extracellular domains, including a ligand-binding domain, a hydrophobic transmembrane region and a tyrosine kinase-containing cytoplasmic region. Stimulation of the EGFR by endogenous ligands, EGF or transforming growth factor-α (TGF-α), results in a conformational change in the receptor, permitting it to enter into dimers and other oligomers. Dimerization results in activation of intracellular tyrosine kinase, protein phosphorylation and stimulation of various cell signaling pathways that mediate gene transcription and cell cycle progression (10) . The EGFR is expressed on normal human cells but higher levels of expression of the receptor have, also, been shown to be correlated with malignancy in a variety of cancers. The activation of the EGFR participates in oncogenesis by inducing cell proliferation, cell mobility and angiogenesis, and inhibiting apoptosis. This activation might be due to numerous abnormalities, including increased expression of its ligand (11) . The current study was designed to evaluate the frequency of HPV infection in patients with LSCC through identification of the viral DNA using PCR analysis and to determine the tissue levels of EGFR as a trial to find a relation between HPV infection, EGFR expression and clinicopathological findings in patients with LSCC. Patients were subjected to full history taking, clinical examination with respect to laryngeal region and underwent CT imaging. Direct laryngoscopy was performed under light general anesthesia in the operating room for evaluation of the larynx and the entire upper aerodigestive tract for accurate clinical staging, to determine the full extent of the local spread of the tumor and to obtain tissue biopsy. Cases were categorized clinically according to TNM classification (12) and only cases with SCC were included in the study.
MATERIALS & METHODS

Sample Preparation
Fresh tumor tissue specimens were divided into two parts, the first was studied and graded pathologically according to the World Health Organization (WHO) classification, (13) and the second was kept frozen at -70 o C until processed and examined by PCR technique for the presence of HPV-DNA and analyzed for EGFR expression.
A-Preparation of Cytosolic and Membrane Fractions
Tumor specimens were finely minced and homogenized in 5 volumes of ice-cold buffer consisting of 25 mM Tris, 1.5 mM EDTA, 5 mM NaN3, 0.1% monothiolglycerol, and 20% glycerol using Plotter-Elvehjem homogenizer. The crude homogenate was centrifuged at 3000 revolve/min (rpm) for 20 min at 0°C, and the supernatant was further centrifuged at 100 rpm for 75 min at 0°C to obtain a cytosolic fraction for a membrane fraction for EGFR assay.
EGFR Measurements
The membrane pellet was resuspended in 25 mM Tris, 1. Fig. 2 ). Fig. 3a-c) . Using ROC curve analysis to determine the specificity of both the presence of HPV infection and tissue expression of EGFR as determinant of the WHO pathological stage revealed that tissue expression of EGFR is more specific with AUC=0.731 while just the presence of viral infection had an AUC=0.583, (Fig. 4) . 
DISCUSSION
Laryngeal carcinoma is the second most common type of head and neck cancer after skin cancer and accounts for 3% of total cancer risk (18) (23) reported that EGFR determination appears to be a powerful prognostic parameter for patients with laryngeal and hypopharyngeal cancer treated by induction chemotherapy followed by exclusive radiotherapy and that laryngectomy seems to erase the prognostic impact of EGFR expression. They concluded that the obtained results prefer the use of EGFR targeting therapy for this category of patients.
Thus, the current study was designed to evaluate the frequency of HPV infection in patients with LSCC through identification of the viral DNA using PCR analysis and to determine the tissue levels of EGFR as a trial to find a relation between HPV infection, EGFR expression and clinicopathological findings in patients with LSCC.
The present study included 29 patients with LSCC with evident sex predilection to occur in males (M:F ratio= 23:6) and with higher percentage of smokers (69%); thus illustrating the relationship between smoking and laryngeal carcinogenesis. These data go in hand with that reported by Alagić-Smailbegović et al.
(24) who reported a frequency of smokers of 93%, however, such high frequency could be attributed to exclusion of female patients in their study and inclusion of only males in whom the frequency of both the disease and smoking is high.
PCR who investigated whether the addition of monoclonal antibodies against the EGFR could enhance the response rate of cisplatin, 5-FU and docetaxel and reported that the combination of cisplatin, 5-FU, docetaxel and the antibody resulted in highly significant complete tumor remissions, with no increased toxicity in the experimental animal. Also, Hitt et al.
(21) reported that in patients with oral SCC, EGFR status and an oral cavity location of the tumor have independent prognostic value in patients with advanced head and neck carcinoma treated with induction chemotherapy.
Furthermore, Psyrri et al. (11) found that patients with oropharyngeal SCC associated with high tumor EGFR expression levels had a local recurrence rate of 58% compared with 17% for patients with low EGFR tumor expression and that patients with high tumor EGFR levels had shorter disease-free survival compared with low expressors and concluded that in multivariate analysis adjusting for prognostic variables, high EGFR expression levels retained their prognostic significance. Pivot et al.
(23) studied potential prognostic factors were age, gender, performance status, primary tumor localization, T status, N status, tumor volume and tumoral EGFR level in patients with laryngeal and hypopharyngeal SCC and reported that EGFR determination appears to be a powerful prognostic parameter for patients treated by induction chemotherapy followed by exclusive radiotherapy.
It could be concluded that laryngeal infection with HPV may predispose to carcinogenesis through activation of certain growth factors as EGF and both were found significantly correlated with the aggressiveness of LSCC with the level of tissue expression of EGFR being a specific determinant of tumor aggressiveness manifested as pathologic stage. 
